{
    "hands_on_practices": [
        {
            "introduction": "Understanding antimicrobial resistance begins at the molecular level. This exercise explores how mutations in a drug's target, such as the mosaic penicillin-binding protein 2 (PBP2) in *N. gonorrhoeae*, can confer resistance by altering binding kinetics. By applying fundamental principles of chemical kinetics, you will quantify how changes in association ($k_{\\mathrm{on}}$) and dissociation ($k_{\\mathrm{off}}$) rates affect the equilibrium dissociation constant ($K_{d}$) and, ultimately, the fractional occupancy of the target at a given drug concentration. ",
            "id": "4672340",
            "problem": "Neisseria gonorrhoeae frequently acquires decreased susceptibility to extended-spectrum cephalosporins through mosaic alterations in penicillin-binding protein 2 (PBP2). Consider the reversible pre-acylation binding step of a cephalosporin drug $D$ to PBP2, modeled as $D + P \\rightleftharpoons DP$ with bimolecular association rate constant $k_{\\mathrm{on}}$ and first-order dissociation rate constant $k_{\\mathrm{off}}$. Under conditions where the reversible binding step reaches quasi-equilibrium rapidly relative to downstream acylation, the equilibrium dissociation constant $K_{d}$ for this step is defined by the law of mass action and depends on the kinetic parameters of the interaction. Assume simple $1{:}1$ binding with no cooperativity and that the total PBP2 concentration is low enough that the free drug concentration can be treated as the nominal $[D]$.\n\nSurface plasmon resonance experiments at $37\\,\\mathrm{^\\circ C}$ yield the following kinetic parameters for ceftriaxone binding to wild-type and mosaic PBP2:\n- Wild-type PBP2: $k_{\\mathrm{on,wt}} = 8.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}$ and $k_{\\mathrm{off,wt}} = 4.0 \\times 10^{-3}\\ \\mathrm{s^{-1}}$.\n- Mosaic PBP2: $k_{\\mathrm{on,mos}} = 3.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}$ and $k_{\\mathrm{off,mos}} = 1.5 \\times 10^{-2}\\ \\mathrm{s^{-1}}$.\n\nAt a free drug concentration of $[D] = 1.0 \\times 10^{-7}\\ \\mathrm{M}$, determine the fold change in equilibrium occupancy of the reversible complex $DP$ for mosaic PBP2 relative to wild-type PBP2, defined as the ratio $\\theta_{\\mathrm{mos}} / \\theta_{\\mathrm{wt}}$, where $\\theta$ denotes the fraction of PBP2 molecules in the $DP$ complex at equilibrium. Round your final ratio to four significant figures and express it as a decimal without a percentage sign.",
            "solution": "The problem is scientifically grounded, well-posed, and objective. All necessary data and definitions for a unique solution are provided. The underlying principles are standard in chemical kinetics and pharmacology, and the biological context is factually correct. Therefore, the problem is valid and a solution can be derived.\n\nThe problem describes the reversible binding of a drug, $D$, to a protein, $P$ (PBP2), to form a complex, $DP$. The reaction is modeled as:\n$$\nD + P \\rightleftharpoons DP\n$$\nThe rate of the forward (association) reaction is given by $R_{\\mathrm{on}} = k_{\\mathrm{on}} [D] [P]$, where $k_{\\mathrm{on}}$ is the bimolecular association rate constant. The rate of the reverse (dissociation) reaction is given by $R_{\\mathrm{off}} = k_{\\mathrm{off}} [DP]$, where $k_{\\mathrm{off}}$ is the first-order dissociation rate constant.\n\nThe problem states that this binding step reaches quasi-equilibrium. At equilibrium, the rate of association equals the rate of dissociation:\n$$\nR_{\\mathrm{on}} = R_{\\mathrm{off}}\n$$\n$$\nk_{\\mathrm{on}} [D] [P] = k_{\\mathrm{off}} [DP]\n$$\nThe equilibrium dissociation constant, $K_d$, is defined by the law of mass action as $K_d = \\frac{[D][P]}{[DP]}$. By rearranging the rate equality, we can express $K_d$ in terms of the kinetic rate constants:\n$$\nK_d = \\frac{k_{\\mathrm{off}}}{k_{\\mathrm{on}}}\n$$\nThe fractional occupancy, $\\theta$, is the fraction of total protein that is in the drug-bound state, $[DP]$. The total protein concentration is $[P]_{\\text{total}} = [P] + [DP]$.\n$$\n\\theta = \\frac{[DP]}{[P]_{\\text{total}}} = \\frac{[DP]}{[P] + [DP]}\n$$\nTo express $\\theta$ in terms of the drug concentration $[D]$ and the dissociation constant $K_d$, we first rearrange the definition of $K_d$ to solve for the free protein concentration, $[P]$:\n$$\n[P] = \\frac{K_d [DP]}{[D]}\n$$\nSubstituting this into the expression for $\\theta$:\n$$\n\\theta = \\frac{[DP]}{\\frac{K_d [DP]}{[D]} + [DP]}\n$$\nThe term $[DP]$ appears in the numerator and in each term of the denominator, so it can be canceled:\n$$\n\\theta = \\frac{1}{\\frac{K_d}{[D]} + 1} = \\frac{[D]}{K_d + [D]}\n$$\nThis is the Hill-Langmuir equation for $1{:}1$ binding.\n\nWe first calculate the equilibrium dissociation constants for the wild-type (wt) and mosaic (mos) forms of PBP2 using the provided kinetic parameters.\n\nFor wild-type PBP2:\n$k_{\\mathrm{on,wt}} = 8.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}$\n$k_{\\mathrm{off,wt}} = 4.0 \\times 10^{-3}\\ \\mathrm{s^{-1}}$\n$$\nK_{d,\\mathrm{wt}} = \\frac{k_{\\mathrm{off,wt}}}{k_{\\mathrm{on,wt}}} = \\frac{4.0 \\times 10^{-3}\\ \\mathrm{s^{-1}}}{8.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}} = 0.5 \\times 10^{-8}\\ \\mathrm{M} = 5.0 \\times 10^{-9}\\ \\mathrm{M}\n$$\nFor mosaic PBP2:\n$k_{\\mathrm{on,mos}} = 3.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}$\n$k_{\\mathrm{off,mos}} = 1.5 \\times 10^{-2}\\ \\mathrm{s^{-1}}$\n$$\nK_{d,\\mathrm{mos}} = \\frac{k_{\\mathrm{off,mos}}}{k_{\\mathrm{on,mos}}} = \\frac{1.5 \\times 10^{-2}\\ \\mathrm{s^{-1}}}{3.0 \\times 10^{5}\\ \\mathrm{M^{-1}\\,s^{-1}}} = 0.5 \\times 10^{-7}\\ \\mathrm{M} = 5.0 \\times 10^{-8}\\ \\mathrm{M}\n$$\nNext, we express the fractional occupancies for both variants using the derived binding equation and the given drug concentration $[D] = 1.0 \\times 10^{-7}\\ \\mathrm{M}$.\n$$\n\\theta_{\\mathrm{wt}} = \\frac{[D]}{K_{d,\\mathrm{wt}} + [D]}\n$$\n$$\n\\theta_{\\mathrm{mos}} = \\frac{[D]}{K_{d,\\mathrm{mos}} + [D]}\n$$\nThe problem asks for the fold change in equilibrium occupancy, which is the ratio $\\frac{\\theta_{\\mathrm{mos}}}{\\theta_{\\mathrm{wt}}}$.\n$$\n\\frac{\\theta_{\\mathrm{mos}}}{\\theta_{\\mathrm{wt}}} = \\frac{\\frac{[D]}{K_{d,\\mathrm{mos}} + [D]}}{\\frac{[D]}{K_{d,\\mathrm{wt}} + [D]}}\n$$\nSimplifying this complex fraction yields:\n$$\n\\frac{\\theta_{\\mathrm{mos}}}{\\theta_{\\mathrm{wt}}} = \\frac{K_{d,\\mathrm{wt}} + [D]}{K_{d,\\mathrm{mos}} + [D]}\n$$\nNow we substitute the calculated $K_d$ values and the given $[D]$:\n$$\n\\frac{\\theta_{\\mathrm{mos}}}{\\theta_{\\mathrm{wt}}} = \\frac{5.0 \\times 10^{-9}\\ \\mathrm{M} + 1.0 \\times 10^{-7}\\ \\mathrm{M}}{5.0 \\times 10^{-8}\\ \\mathrm{M} + 1.0 \\times 10^{-7}\\ \\mathrm{M}}\n$$\nTo facilitate the addition, we can express all concentrations with a common power of $10$, for instance $10^{-7}$:\n$$\n\\frac{\\theta_{\\mathrm{mos}}}{\\theta_{\\mathrm{wt}}} = \\frac{0.05 \\times 10^{-7}\\ \\mathrm{M} + 1.0 \\times 10^{-7}\\ \\mathrm{M}}{0.5 \\times 10^{-7}\\ \\mathrm{M} + 1.0 \\times 10^{-7}\\ \\mathrm{M}} = \\frac{(0.05 + 1.0) \\times 10^{-7}\\ \\mathrm{M}}{(0.5 + 1.0) \\times 10^{-7}\\ \\mathrm{M}}\n$$\n$$\n\\frac{\\theta_{\\mathrm{mos}}}{\\theta_{\\mathrm{wt}}} = \\frac{1.05 \\times 10^{-7}\\ \\mathrm{M}}{1.5 \\times 10^{-7}\\ \\mathrm{M}} = \\frac{1.05}{1.5} = 0.7\n$$\nThe calculated ratio is exactly $0.7$. The problem requires the final answer to be rounded to four significant figures. Therefore, the result should be expressed as $0.7000$. This indicates that at a drug concentration of $1.0 \\times 10^{-7}\\ \\mathrm{M}$, the occupancy of the mosaic PBP2 is $70\\%$ of the occupancy of the wild-type PBP2.",
            "answer": "$$\\boxed{0.7000}$$"
        },
        {
            "introduction": "While target modification is a critical resistance mechanism, a drug's ability to reach its intracellular target is equally important. This practice builds a biophysical model of the bacterial cell to connect the clinically measured Minimum Inhibitory Concentration (MIC) to underlying transport dynamics. You will derive how antibiotic influx via porins and active efflux balance to determine the steady-state intracellular drug concentration, and then use this model to calculate how a mutation affecting outer membrane permeability leads to a quantifiable increase in resistance. ",
            "id": "4672294",
            "problem": "A research group is studying how alterations in the porin protein B (porB) of Neisseria gonorrhoeae affect antibiotic susceptibility by changing trans-outer-membrane permeability. For a hydrophilic, non-metabolized cephalosporin whose intracellular target requires an inhibitory concentration $C^{\\star}$ to halt bacterial growth, consider the following biophysical model:\n\n- Passive influx across the outer membrane is driven by a concentration difference and obeys a linear flux law $J = P\\,(C_{\\mathrm{out}} - C_{\\mathrm{in}})$, where $J$ is flux per unit area, $P$ is the permeability coefficient, $C_{\\mathrm{out}}$ is the external concentration, and $C_{\\mathrm{in}}$ is the intracellular concentration.\n- Net intracellular antibiotic dynamics are governed by a mass balance that assumes first-order efflux with rate constant $k_{e}$ and negligible intracellular metabolism or degradation on the timescale of interest.\n- The bacterium is approximated as a sphere of radius $r$, so its surface-to-volume ratio is $A/V = 3/r$.\n\nIn the wild-type strain, independent uptake experiments estimate the permeability coefficient to be $P = 2.0 \\times 10^{-5}\\,\\mathrm{cm}\\,\\mathrm{s}^{-1}$, the first-order efflux rate constant to be $k_{e} = 0.60\\,\\mathrm{s}^{-1}$, and the effective cell radius to be $r = 0.50\\,\\mu\\mathrm{m}$. A porB point mutation is subsequently observed to increase the Minimum Inhibitory Concentration (MIC) by a factor of $s = 3.0$ relative to the wild-type, while leaving efflux kinetics and target inhibition requirements unchanged.\n\nStarting from the stated transport law, the mass balance, and the spherical geometry, derive the relationship between MIC and the parameters $\\{P, k_{e}, r\\}$ under steady-state intracellular conditions ($dC_{\\mathrm{in}}/dt = 0$) required to achieve $C_{\\mathrm{in}} = C^{\\star}$. Then, using these premises and the measured MIC shift $s$, compute the dimensionless ratio of mutant to wild-type permeability $P'/P$. Provide your final answer as a single real number. Do not include units.",
            "solution": "The problem requires the derivation of a relationship for the Minimum Inhibitory Concentration (MIC) and its subsequent use to determine the change in membrane permeability in a mutant bacterium. The solution proceeds in two stages: first, deriving the general formula for MIC based on the provided biophysical model, and second, applying this formula to the wild-type and mutant strains to find the permeability ratio.\n\nFirst, we establish the mass balance for the intracellular antibiotic concentration, $C_{\\mathrm{in}}$. The rate of change of the amount of antibiotic inside the cell, which is the product of intracellular concentration and cell volume $V$, is given by the difference between the total influx rate and the total efflux rate.\n\nThe total influx rate is the flux per unit area, $J$, multiplied by the cell surface area, $A$. The flux is given by $J = P(C_{\\mathrm{out}} - C_{\\mathrm{in}})$, where $P$ is the permeability coefficient and $C_{\\mathrm{out}}$ is the external concentration.\n$$ \\text{Rate of Influx} = J A = P(C_{\\mathrm{out}} - C_{\\mathrm{in}})A $$\n\nThe efflux is a first-order process with rate constant $k_e$. The total rate of efflux is thus proportional to the amount of antibiotic inside, $C_{\\mathrm{in}}V$.\n$$ \\text{Rate of Efflux} = k_e C_{\\mathrm{in}}V $$\n\nThe differential equation for the intracellular amount, $C_{\\mathrm{in}}V$, is:\n$$ \\frac{d(C_{\\mathrm{in}}V)}{dt} = P(C_{\\mathrm{out}} - C_{\\mathrm{in}})A - k_e C_{\\mathrm{in}}V $$\nSince the cell volume $V$ is constant, we can divide by $V$ to obtain the equation for the rate of change of concentration:\n$$ \\frac{dC_{\\mathrm{in}}}{dt} = P(C_{\\mathrm{out}} - C_{\\mathrm{in}})\\frac{A}{V} - k_e C_{\\mathrm{in}} $$\nThe problem specifies that the bacterium is a sphere of radius $r$, for which the surface-to-volume ratio is given as $A/V = 3/r$. Substituting this into the equation yields:\n$$ \\frac{dC_{\\mathrm{in}}}{dt} = P(C_{\\mathrm{out}} - C_{\\mathrm{in}})\\frac{3}{r} - k_e C_{\\mathrm{in}} $$\n\nThe MIC is defined as the external concentration, $C_{\\mathrm{out}}$, at which a steady-state ($dC_{\\mathrm{in}}/dt = 0$) intracellular concentration equal to the inhibitory concentration, $C^{\\star}$, is achieved. We set $dC_{\\mathrm{in}}/dt = 0$, $C_{\\mathrm{in}} = C^{\\star}$, and $C_{\\mathrm{out}} = \\mathrm{MIC}$:\n$$ 0 = P(\\mathrm{MIC} - C^{\\star})\\frac{3}{r} - k_e C^{\\star} $$\nWe now rearrange this equation to solve for MIC. This provides the required relationship between MIC and the parameters $\\{P, k_e, r\\}$.\n$$ P(\\mathrm{MIC} - C^{\\star})\\frac{3}{r} = k_e C^{\\star} $$\n$$ \\mathrm{MIC} - C^{\\star} = \\frac{k_e C^{\\star} r}{3P} $$\n$$ \\mathrm{MIC} = C^{\\star} + \\frac{k_e C^{\\star} r}{3P} $$\n$$ \\mathrm{MIC} = C^{\\star} \\left( 1 + \\frac{k_e r}{3P} \\right) $$\n\nNext, we apply this formula to both the wild-type and the mutant strains. Let the wild-type parameters be $P$, $k_e$, $r$ and the resulting MIC be $\\mathrm{MIC_{wt}}$. Let the mutant parameters be $P'$, $k_e'$, $r'$ and the resulting MIC be $\\mathrm{MIC_{mut}}$. The problem states that $k_e' = k_e$, $r' = r$, and the target inhibition concentration $C^{\\star}$ is also unchanged. The permeability is altered to $P'$. The MIC of the mutant is a factor of $s$ larger than the wild-type, so $\\mathrm{MIC_{mut}} = s \\cdot \\mathrm{MIC_{wt}}$.\n\nFor the wild-type strain:\n$$ \\mathrm{MIC_{wt}} = C^{\\star} \\left( 1 + \\frac{k_e r}{3P} \\right) $$\n\nFor the mutant strain:\n$$ \\mathrm{MIC_{mut}} = C^{\\star} \\left( 1 + \\frac{k_e r}{3P'} \\right) $$\n\nWe form the ratio $\\mathrm{MIC_{mut}}/\\mathrm{MIC_{wt}} = s$:\n$$ s = \\frac{C^{\\star} \\left( 1 + \\frac{k_e r}{3P'} \\right)}{C^{\\star} \\left( 1 + \\frac{k_e r}{3P} \\right)} = \\frac{1 + \\frac{k_e r}{3P'}}{1 + \\frac{k_e r}{3P}} $$\nOur goal is to solve for the ratio $P'/P$. We can rearrange the equation for $P'/P$:\n$$ s \\left( 1 + \\frac{k_e r}{3P} \\right) = 1 + \\frac{k_e r}{3P'} $$\n$$ s + \\frac{s k_e r}{3P} - 1 = \\frac{k_e r}{3P'} $$\n$$ (s-1) + \\frac{s k_e r}{3P} = \\frac{k_e r}{3P'} $$\nMultiplying by $3P'/(k_e r)$ gives:\n$$ \\frac{3P'}{k_e r} \\left( (s-1) + \\frac{s k_e r}{3P} \\right) = 1 $$\n$$ \\frac{3P'(s-1)}{k_e r} + \\frac{P'}{P} s = 1 $$\n$$ \\frac{P'}{P} \\left( \\frac{3P(s-1)}{k_e r} + s \\right) = 1 $$\n$$ \\frac{P'}{P} = \\frac{1}{\\frac{3P(s-1)}{k_e r} + s} = \\frac{\\frac{k_e r}{3P}}{s-1 + s \\frac{k_e r}{3P}} $$\nAn alternative algebraic path is to define a dimensionless quantity $X = \\frac{k_e r}{3P}$. The ratio equation becomes:\n$$ s = \\frac{1 + \\frac{k_e r}{3P'}}{1 + X} = \\frac{1 + \\frac{P}{P'}X}{1+X} $$\nSolving for $P'/P$:\n$$ s(1+X) = 1 + \\frac{X}{P'/P} \\implies \\frac{X}{P'/P} = s(1+X) - 1 $$\n$$ \\frac{P'}{P} = \\frac{X}{s(1+X) - 1} $$\n\nWe now compute the dimensionless number $X$ using the given wild-type parameters. We must ensure consistent units.\n$P = 2.0 \\times 10^{-5}\\,\\mathrm{cm}\\,\\mathrm{s}^{-1}$\n$k_{e} = 0.60\\,\\mathrm{s}^{-1}$\n$r = 0.50\\,\\mu\\mathrm{m} = 0.50 \\times 10^{-4}\\,\\mathrm{cm}$\n$$ X = \\frac{k_e r}{3P} = \\frac{(0.60\\,\\mathrm{s}^{-1})(0.50 \\times 10^{-4}\\,\\mathrm{cm})}{3(2.0 \\times 10^{-5}\\,\\mathrm{cm}\\,\\mathrm{s}^{-1})} $$\n$$ X = \\frac{0.30 \\times 10^{-4}}{6.0 \\times 10^{-5}} = \\frac{3.0 \\times 10^{-5}}{6.0 \\times 10^{-5}} = \\frac{1}{2} = 0.5 $$\n\nThe MIC increase factor is given as $s = 3.0$. Substituting the values of $X$ and $s$ into our expression for the permeability ratio:\n$$ \\frac{P'}{P} = \\frac{0.5}{3.0(1 + 0.5) - 1} $$\n$$ \\frac{P'}{P} = \\frac{0.5}{3.0(1.5) - 1} $$\n$$ \\frac{P'}{P} = \\frac{0.5}{4.5 - 1} $$\n$$ \\frac{P'}{P} = \\frac{0.5}{3.5} = \\frac{5}{35} = \\frac{1}{7} $$\nThe ratio of the mutant permeability to the wild-type permeability is $1/7$.",
            "answer": "$$\\boxed{\\frac{1}{7}}$$"
        },
        {
            "introduction": "Moving from the cellular to the population level, effective surveillance and control of gonorrhea depend on accurate diagnostic testing. This exercise demonstrates that a test's real-world performance is not solely determined by its intrinsic sensitivity and specificity, but also by the characteristics of the population being tested. Using Bayes' theorem, you will calculate the Positive and Negative Predictive Values ($PPV$ and $NPV$) for a screening program that aggregates results from different anatomical sites, providing a quantitative understanding of the challenges in interpreting diagnostic data in public health practice. ",
            "id": "4672268",
            "problem": "A public health clinic deploys a Nucleic Acid Amplification Test (NAAT) for detection of Neisseria gonorrhoeae across two specimen types that differ in performance due to biological and ecological factors. The definitions to be used are: sensitivity is $P(\\text{Test} + \\mid \\text{Disease})$, specificity is $P(\\text{Test} - \\mid \\neg \\text{Disease})$, and prevalence is $P(\\text{Disease})$. The clinic tests one specimen per patient, with a known mixture of specimen types. Empirically, for urogenital specimens ($u$), the sensitivity is $s_{u} = 0.97$, the specificity is $c_{u} = 0.995$, and the prevalence among those tested is $p_{u} = 0.08$. For pharyngeal specimens ($p$), the sensitivity is $s_{p} = 0.92$, the specificity is $c_{p} = 0.985$, and the prevalence among those tested is $p_{p} = 0.05$. The specimen-type mix is $w_{u} = 0.60$ urogenital and $w_{p} = 0.40$ pharyngeal, with $w_{u} + w_{p} = 1$.\n\nAssume the test outcome for a given specimen type is conditionally independent of population mixing beyond its dependence on the specimen type and true disease status, and that the biological definitions above hold exactly. Using Bayesâ€™ theorem and the law of total probability applied across the specimen-type mixture, compute the overall positive predictive value $PPV = P(\\text{Disease} \\mid \\text{Test} +)$ and negative predictive value $NPV = P(\\neg \\text{Disease} \\mid \\text{Test} -)$ for the aggregate NAAT results produced by this program. Report both $PPV$ and $NPV$ as decimal values rounded to four significant figures.",
            "solution": "The problem is valid as it is scientifically grounded in epidemiology, well-posed with all necessary information, and free of contradictions or ambiguities. We proceed with the solution.\n\nLet the following events be defined:\n- $D$: The patient has the disease (*Neisseria gonorrhoeae* infection).\n- $\\neg D$: The patient does not have the disease.\n- $T+$: The NAAT result is positive.\n- $T-$: The NAAT result is negative.\n- $U$: The specimen is urogenital.\n- $P$: The specimen is pharyngeal.\n\nThe provided parameters can be expressed in probabilistic terms:\n- Sensitivity for urogenital specimens: $s_u = P(T+ \\mid D, U) = 0.97$\n- Specificity for urogenital specimens: $c_u = P(T- \\mid \\neg D, U) = 0.995$\n- Prevalence in the urogenital-tested subpopulation: $p_u = P(D \\mid U) = 0.08$\n- Sensitivity for pharyngeal specimens: $s_p = P(T+ \\mid D, P) = 0.92$\n- Specificity for pharyngeal specimens: $c_p = P(T- \\mid \\neg D, P) = 0.985$\n- Prevalence in the pharyngeal-tested subpopulation: $p_p = P(D \\mid P) = 0.05$\n- Proportion of urogenital specimens: $w_u = P(U) = 0.60$\n- Proportion of pharyngeal specimens: $w_p = P(P) = 0.40$\n\nWe need to compute the overall positive predictive value, $PPV = P(D \\mid T+)$, and the overall negative predictive value, $NPV = P(\\neg D \\mid T-)$.\n\nBy definition of conditional probability (Bayes' theorem):\n$$PPV = P(D \\mid T+) = \\frac{P(D \\cap T+)}{P(T+)}$$\n$$NPV = P(\\neg D \\mid T-) = \\frac{P(\\neg D \\cap T-)}{P(T-)}$$\n\nWe will compute the components of these expressions using the law of total probability, conditioning on the specimen type ($U$ or $P$).\n\nFirst, we calculate the numerator for the $PPV$, which is the total probability of having the disease and testing positive, $P(D \\cap T+)$.\n$$P(D \\cap T+) = P(D \\cap T+ \\mid U)P(U) + P(D \\cap T+ \\mid P)P(P)$$\nUsing the definition of conditional probability, $P(A \\cap B \\mid C) = P(A \\mid B, C)P(B \\mid C)$:\n$$P(D \\cap T+) = P(T+ \\mid D, U)P(D \\mid U)P(U) + P(T+ \\mid D, P)P(D \\mid P)P(P)$$\nSubstituting the given symbolic names:\n$$P(D \\cap T+) = s_u p_u w_u + s_p p_p w_p$$\n$$P(D \\cap T+) = (0.97)(0.08)(0.60) + (0.92)(0.05)(0.40)$$\n$$P(D \\cap T+) = 0.04656 + 0.0184 = 0.06496$$\n\nNext, we calculate the denominator for the $PPV$, which is the total probability of testing positive, $P(T+)$.\n$$P(T+) = P(T+ \\mid D)P(D) + P(T+ \\mid \\neg D)P(\\neg D)$$\nAn alternative and more direct approach is to sum the joint probabilities of a positive test with disease and without disease:\n$$P(T+) = P(T+ \\cap D) + P(T+ \\cap \\neg D)$$\nWe already have $P(T+ \\cap D) = 0.06496$. We now compute $P(T+ \\cap \\neg D)$.\nUsing the law of total probability again:\n$$P(T+ \\cap \\neg D) = P(T+ \\mid \\neg D, U)P(\\neg D \\mid U)P(U) + P(T+ \\mid \\neg D, P)P(\\neg D \\mid P)P(P)$$\nWe use the fact that specificity $c = P(T- \\mid \\neg D)$, so $P(T+ \\mid \\neg D) = 1 - c$. Also, $P(\\neg D \\mid S) = 1 - P(D \\mid S) = 1 - p_S$ for specimen type $S$.\n$$P(T+ \\cap \\neg D) = (1-c_u)(1-p_u)w_u + (1-c_p)(1-p_p)w_p$$\n$$P(T+ \\cap \\neg D) = (1-0.995)(1-0.08)(0.60) + (1-0.985)(1-0.05)(0.40)$$\n$$P(T+ \\cap \\neg D) = (0.005)(0.92)(0.60) + (0.015)(0.95)(0.40)$$\n$$P(T+ \\cap \\neg D) = 0.00276 + 0.0057 = 0.00846$$\nNow, we can find the total probability of a positive test:\n$$P(T+) = 0.06496 + 0.00846 = 0.07342$$\nFinally, we compute the $PPV$:\n$$PPV = \\frac{P(D \\cap T+)}{P(T+)} = \\frac{0.06496}{0.07342} \\approx 0.88477254...$$\nRounding to four significant figures, $PPV = 0.8848$.\n\nNow, we compute the $NPV$. First, we calculate the numerator, $P(\\neg D \\cap T-)$.\n$$P(\\neg D \\cap T-) = P(T- \\mid \\neg D, U)P(\\neg D \\mid U)P(U) + P(T- \\mid \\neg D, P)P(\\neg D \\mid P)P(P)$$\n$$P(\\neg D \\cap T-) = c_u(1-p_u)w_u + c_p(1-p_p)w_p$$\n$$P(\\neg D \\cap T-) = (0.995)(1-0.08)(0.60) + (0.985)(1-0.05)(0.40)$$\n$$P(\\neg D \\cap T-) = (0.995)(0.92)(0.60) + (0.985)(0.95)(0.40)$$\n$$P(\\neg D \\cap T-) = 0.54924 + 0.3743 = 0.92354$$\n\nNext, we calculate the denominator, $P(T-)$. The simplest way is to use the complement of $P(T+)$.\n$$P(T-) = 1 - P(T+) = 1 - 0.07342 = 0.92658$$\nAlternatively, we can compute it from its components: $P(T-) = P(T- \\cap D) + P(T- \\cap \\neg D)$. We have $P(T- \\cap \\neg D) = 0.92354$. We need $P(T- \\cap D)$.\n$$P(T- \\cap D) = P(T- \\mid D, U)P(D \\mid U)P(U) + P(T- \\mid D, P)P(D \\mid P)P(P)$$\nUsing $P(T- \\mid D) = 1 - s$:\n$$P(T- \\cap D) = (1-s_u)p_u w_u + (1-s_p)p_p w_p$$\n$$P(T- \\cap D) = (1-0.97)(0.08)(0.60) + (1-0.92)(0.05)(0.40)$$\n$$P(T- \\cap D) = (0.03)(0.08)(0.60) + (0.08)(0.05)(0.40)$$\n$$P(T- \\cap D) = 0.00144 + 0.0016 = 0.00304$$\nSo, $P(T-) = P(T- \\cap \\neg D) + P(T- \\cap D) = 0.92354 + 0.00304 = 0.92658$. This confirms the result from $1-P(T+)$.\n\nFinally, we compute the $NPV$:\n$$NPV = \\frac{P(\\neg D \\cap T-)}{P(T-)} = \\frac{0.92354}{0.92658} \\approx 0.9967190...$$\nRounding to four significant figures, $NPV = 0.9967$.\n\nThe overall Positive Predictive Value ($PPV$) is $0.8848$ and the overall Negative Predictive Value ($NPV$) is $0.9967$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n0.8848 & 0.9967\n\\end{pmatrix}\n}\n$$"
        }
    ]
}